New Delhi 8, February 2013: Becton Dickinson (BD) India in partnership with National Accredition Board for Hospitals (NABH) has embarked on a nationwide plan to help hospitals acquire NABH-Safe-ITSM Certification program for infection control to deliver safe healthcare to patients. The first hospital to get the certification, Tagore Hospital is one of the 21 hospitals undergoing the NABH-Safe-ITSMaccreditation programme from Punjab and Kerala, the 2 states under the pilot started in March 2012.
The NABH-Safe-ITSMcertification for infection control is an important cornerstone of safe healthcare delivery recognising that many small hospitals lack the resources and managerial bandwidth to achieve the main NABH certification.
Under this program, NABH recommends safe injection and infusion practices, biomedical waste management, healthcare workers safety and sterilization and disinfection, to name a few. NABH also provides a consultant through its technical partner – BD to help applicants build capability to run a robust infection control program, providing training content and surveillance tools, as well as conducting a baseline and an end-line assessment post the training, basis which the applicant hospital knows when its ready to invite NABH assessors.
Manoj Gopalakrishna, Managing Director, BD India said, “BD has always worked toward achieving our purpose of helping all people live healthy lives. The NABH-Safe-ITSM certification is an innovative collaboration for enhancing patient safety and healthcare worker safety and will augment infection control standards in the hospitals of India.”
Approaching quality as a journey, rather than a destination, it is hoped that this certification will serve as a stepping stone for the hospital to achieve the full NABH accreditation easily in future.
Dr. KK Kalra, CEO, National Accreditation Board for Hospitals (NABH) said, “NABH is currently operating in India with nearly 864 hospitals in various phases of accreditation and 156 large hospitals are already accredited. There is a need for increased awareness among the healthcare facilities across India so that more healthcare organizations start participating in quality initiatives. There is a role for all the concerned stakeholders towards raising awareness and involving healthcare organizations to adopt quality standards.”
NABH and BD had entered a Memorandum of Understanding (MoU) in 2012 to support hospitals in attaining quality-of-care standards for infection control in three phases. During Phase One, initial workshops were to be carried out across hospitals in India to ensure adoption of ‘Safe-ITSM’ by hospitals as a stepping stone towards achieving quality. The second phase will offer Centers of Excellence (CoE) and Health Economic models to be developed for the benefit of Indian Healthcare after dissemination of NABH-Safe-ITSM program. The last phase will augment national capability of standards dissemination by developing additional Centers of Excellence.
Patient safety and quality in healthcare in healthcare facilities is the need of the hour across the world and so in India. Hospital infections are a big concern and NABH (National Accreditation Board for Hospitals & Healthcare Providers) standards for infection control are the most important standards of NABH accreditation program. An effective infection control program is in fact the stepping stone towards NABH accreditation for those hospitals that have not yet started the journey towards accreditation.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.